Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,828,191 papers from all fields of science
Search
Sign In
Create Free Account
L 689660
Known as:
L-689,660
, L-689660
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Bridged Bicyclo Compounds, Heterocyclic
Pyrazines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
A comparison of the effects of the novel muscarinic receptor agonists L-689,660 and AF102B in tests of reference and working memory
G. Dawson
,
P. Bayley
,
S. Channell
,
S. Iversen
Psychopharmacology
2005
Corpus ID: 24171627
Four experiments compared the CNS effects of a novel M1/M3 receptor agonist L-689,660 with those of the M1/M3 muscarinic receptor…
Expand
Review
1993
Review
1993
The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo.
S. Freedman
,
G. Dawson
,
L. Iversen
,
R. Baker
,
R. Hargreaves
Life Science
1993
Corpus ID: 23030967
1993
1993
Pharmacological characterization of the novel cholinomimetic L-689,660 at cloned and native brain muscarinic receptors.
P. Aagaard
,
M. Mckinney
Journal of Pharmacology and Experimental…
1993
Corpus ID: 19841987
1-Azabicyclo[2,2,2]octane,3-(6-chloropyrazinyl)maleate (L-689,660) reportedly is an agonist with selectivity for M1 and M3…
Expand
1992
1992
L‐689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors
R. Hargreaves
,
A. Mcknight
,
+7 authors
S. Freedman
British Journal of Pharmacology
1992
Corpus ID: 8568953
1 L‐689,660, 1‐azabicyclo[2.2.2]octane, 3‐(6‐chloropyrazinyl)maleate, a novel cholinomimetic, demonstrated high affinity binding…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE